Keywords: Quantitative Imaging, Breast
Motivation: HER-2 expression in breast cancer is key for personalized treatment but often requires invasive biopsy. MRI-based quantitative imaging, particularly MDME synthetic T1 and T2 mapping or DWI, may offer a non-invasive, efficient alternative.
Goal(s): To evaluate the clinical value of T1, T2, and ADC measurements for predicting HER-2 expression in breast cancer.
Approach: In 58 breast cancer patients, MDME rapidly acquired T1 and T2 mappings with multiple contrast images, while DWI provided ADC values. Statistical analysis revealed differences across HER-2 expression levels.
Results: T2 values and combined model showed significant predictive power for HER-2 expression, supporting MDME as a non-invasive diagnostic tool.
Impact: MDME-based T1 and T2 mappings combined with DWI offers a rapid, non-invasive method for predicting HER-2 expression in breast cancer, potentially reducing the need for biopsy and supporting preoperative decision-making.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords